Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» IBI302
IBI302
Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial
Fierce Biotech
Tue, 03/19/24 - 11:21 am
Innovent
Regeneron
Bayer
anti-VEGF
neovascular age-related macular degeneration
IBI302
Eylea